Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr.

N Engl J Med. 2004 May 27;350(22):2239-46. Erratum in: N Engl J Med. 2004 Sep 30;351(14):1470.

3.

The influence of finasteride on the development of prostate cancer.

Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr.

N Engl J Med. 2003 Jul 17;349(3):215-24. Epub 2003 Jun 24.

4.

Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.

Horninger W, Cheli CD, Babaian RJ, Fritsche HA, Lepor H, Taneja SS, Childs S, Stamey TA, Sokoll LJ, Chan DW, Brawer MK, Partin AW, Bartsch G.

Urology. 2002 Oct;60(4 Suppl 1):31-5.

PMID:
12384160
5.

Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.

Törnblom M, Norming U, Adolfsson J, Becker C, Abrahamsson PA, Lilja H, Gustafsson O.

Urology. 1999 May;53(5):945-50.

PMID:
10223488
6.

Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.

Walz J, Haese A, Scattoni V, Steuber T, Chun FK, Briganti A, Montorsi F, Graefen M, Huland H, Karakiewicz PI.

Cancer. 2008 Nov 15;113(10):2695-703. doi: 10.1002/cncr.23885.

7.

Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.

Ahyai SA, Graefen M, Steuber T, Haese A, Schlomm T, Walz J, Köllermann J, Briganti A, Zacharias M, Friedrich MG, Karakiewicz PI, Montorsi F, Huland H, Chun FK.

Eur Urol. 2008 Apr;53(4):750-7. Epub 2007 Oct 17.

PMID:
17964070
8.
9.
10.

Prostate-specific antigen velocity and prostate cancer gleason grade and stage.

Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, Greenlee R, Gohagan JK.

Cancer. 2007 Apr 15;109(8):1689-95.

12.

Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.

Mäkinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, Juusela H, Määttänen L, Auvinen A.

J Urol. 2001 Oct;166(4):1339-42.

PMID:
11547069
13.

Clinical usefulness of free PSA in early detection of prostate cancer.

Luboldt HJ, Swoboda A, Börgermann C, Fornara P, Rübben H; Early Detection Project Group of the German Society of Urology.

Onkologie. 2001 Feb;24(1):33-7.

PMID:
11441278
14.

Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.

Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr.

J Clin Oncol. 2007 Jul 20;25(21):3076-81.

PMID:
17634486
15.
16.

Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.

Etzioni RD, Howlader N, Shaw PA, Ankerst DP, Penson DF, Goodman PJ, Thompson IM.

J Urol. 2005 Sep;174(3):877-81. Erratum in: J Urol. 2005 Nov;174(5):2071.

PMID:
16093979
17.

Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.

Punglia RS, Cullen J, McLeod DG, Chen Y, D'Amico AV.

Cancer. 2007 Nov 1;110(9):1973-8.

18.
19.

Prostate carcinoma screening in the county of Tyrol, Austria: experience and results.

Reissigl A, Horninger W, Fink K, Klocker H, Bartsch G.

Cancer. 1997 Nov 1;80(9):1818-29.

PMID:
9351555

Supplemental Content

Support Center